US drug delivery product demand will rise 7.4 percent yearly to $134 billion in 2015. Parenteral products will grow the fastest, led by monoclonal antibodies and polymer-encapsulated medicines. Other types expected to do well include prefilled dry powder and metered dose brachytherapy implants, and implantable drug delivery products.
This study analyzes the $93.8 billion US drug delivery system industry. It presents historical demand data for the years 2000, 2005 and 2010, and forecasts for 2015 and 2020 by excipient (e.g., polymers, cellulose, minerals), product type (e.g., oral, parenteral, inhalation, implantable, transdermal) and application (e.g., central nervous system, respiratory, hormones, gastrointestinal).
The study also considers market environment factors, details industry structure, evaluates company market share and profiles 27 industry players, including Roche, GlaxoSmithKline and Becton Dickinson.
